Ruxolitinib (RUX) + Best Available Therapy (BAT)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Corticosteroid Refractory Acute Graft vs Host Disease
Conditions
Corticosteroid Refractory Acute Graft vs Host Disease
Trial Timeline
Mar 10, 2017 → Apr 23, 2021
NCT ID
NCT02913261About Ruxolitinib (RUX) + Best Available Therapy (BAT)
Ruxolitinib (RUX) + Best Available Therapy (BAT) is a phase 3 stage product being developed by Novartis for Corticosteroid Refractory Acute Graft vs Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02913261. Target conditions include Corticosteroid Refractory Acute Graft vs Host Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02913261 | Phase 3 | Completed |
Competing Products
1 competing product in Corticosteroid Refractory Acute Graft vs Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levetiracetam, Keppra | UCB | Approved | 82 |